1. Home
  2. CSTL vs FPI Comparison

CSTL vs FPI Comparison

Compare CSTL & FPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSTL
  • FPI
  • Stock Information
  • Founded
  • CSTL 2007
  • FPI 2013
  • Country
  • CSTL United States
  • FPI United States
  • Employees
  • CSTL N/A
  • FPI N/A
  • Industry
  • CSTL Medical Specialities
  • FPI Real Estate Investment Trusts
  • Sector
  • CSTL Health Care
  • FPI Real Estate
  • Exchange
  • CSTL Nasdaq
  • FPI Nasdaq
  • Market Cap
  • CSTL 555.8M
  • FPI 478.7M
  • IPO Year
  • CSTL 2019
  • FPI 2014
  • Fundamental
  • Price
  • CSTL $24.21
  • FPI $10.67
  • Analyst Decision
  • CSTL Strong Buy
  • FPI
  • Analyst Count
  • CSTL 6
  • FPI 0
  • Target Price
  • CSTL $37.67
  • FPI N/A
  • AVG Volume (30 Days)
  • CSTL 712.7K
  • FPI 302.7K
  • Earning Date
  • CSTL 08-04-2025
  • FPI 10-29-2025
  • Dividend Yield
  • CSTL N/A
  • FPI 2.25%
  • EPS Growth
  • CSTL N/A
  • FPI 229.01
  • EPS
  • CSTL N/A
  • FPI 1.21
  • Revenue
  • CSTL $346,269,000.00
  • FPI $55,000,000.00
  • Revenue This Year
  • CSTL N/A
  • FPI N/A
  • Revenue Next Year
  • CSTL N/A
  • FPI N/A
  • P/E Ratio
  • CSTL N/A
  • FPI $8.85
  • Revenue Growth
  • CSTL 20.40
  • FPI N/A
  • 52 Week Low
  • CSTL $14.59
  • FPI $9.66
  • 52 Week High
  • CSTL $35.84
  • FPI $12.87
  • Technical
  • Relative Strength Index (RSI)
  • CSTL 76.51
  • FPI 41.89
  • Support Level
  • CSTL $20.35
  • FPI $10.90
  • Resistance Level
  • CSTL $20.80
  • FPI $11.12
  • Average True Range (ATR)
  • CSTL 0.95
  • FPI 0.17
  • MACD
  • CSTL 0.45
  • FPI 0.02
  • Stochastic Oscillator
  • CSTL 96.67
  • FPI 8.16

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About FPI Farmland Partners Inc.

Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.

Share on Social Networks: